Australia's largest stock trading and investment forum Australia's #1 stock forum

SNT syntara limited

5.00%

6.3¢

Just stumbled upon this analyst, calls Geron a buy and 12 month...

First 9 Last

Share
Profile

Follow
pinch2020

946 Posts.

606

14/11/24

13:12

Post #: 76604851
Share

Originally posted by pinch2020: ↑

https://www.biospace.com/drug-development/syros-crashes-over-90-on-late-stage-mds-fail-loan-defaultAnother failed myelodysplastic syndrome trial.

https://www.biospace.com/fda-approves-geron-s-first-in-class-telomerase-inhibitor-for-blood-disorder

This was approved for myelodysplastic syndrome back in June

Rytelo is approved for myelodysplastic syndromes (MDS) patients with transfusion-dependent anemia who do not respond or are ineligible for the standard-of-care treatment, erythropoiesis-stimulating agents (ESA)

Achieved $28.2 million in RYTELO™ (imetelstat) net product revenue in first full quarter of sales

"These results also reflect the high unmet need in lower-risk MDS and the compelling value proposition of RYTELO"

Here's a list of Imetelstat's possible side effects.

Low White Blood Cell Count (Leukopenia or Neutropenia)
Low Platelet Count (Thrombocytopenia)
Liver ToxicityFatigue
Joint or Muscle Pain
Less common, but important side effects can include: Reproductive Concerns

SNT- 5055 No side effects

Geron has a similar pipeline to us, looking at MDS and MF. In my opinion our pipeline is a lot more attractive though when you add on scar treatment and organ fibrosis in cancer.

Geron market cap $2.33 billion US.

Back in August 2023, BMS got a label extension for Reblozyl. It was first approved in 2020 but only in patients who had failed to respond to an erythropoiesis-stimulating agent (ESA), the historically front-line treatment.

FDA Approves Bristol Myers Squibb’s Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions

GlobalData analysts project Reblozyl sales to reach $3.2 billion by 2029, while BMS has set its sights on $4 billion-plus aspirations for the drug.BMS had $12.47 billion Aus cash on hand in September. Another possible suitor who I'd suggest is keeping a very close eye on us.

Expand

Just stumbled upon this analyst, calls Geron a buy and 12 month forecast is double the current evaluation. Starts just before the 26 min mark and thinks Imetelstat can get to at least $1bill for lower-risk MDS alone. Hmmmm SNT- 5505 looking at High risk and low/intermediate.....

SNT Price at posting: 3.7¢ Sentiment: Buy Disclosure: Held
8 Upvote

2 Great analysis

Reply

Top Stories

HAR

Haranga jumps +7% on Lincoln acquisition

ASX Market Close: Index rebounds as investors buoyant | July 30, 2025

HotCopper Trends: Wall of quarterlies dominate; then there's Micro-X & Ionic

NUZ

Neurizon inks $1.5M loan against R&D Tax Rebate

IXR

Ionic Rare Earths falls -7% as momentum slips on vague production update

First 9 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 6.3¢		Change 0.003(5.00%)		Mkt cap ! $102.4M

Open	High	Low	Value	Volume
6.0¢	6.4¢	6.0¢	$110.3K	1.768M

Buyers (Bids)

No.	Vol.	Price($)
1	136674	6.3¢

Sellers (Offers)

Price($)	Vol.	No.
6.4¢	215185	2

View Market Depth

No.	Vol.	Price($)
1	136674	0.063
1	226979	0.062
1	200000	0.061
4	233331	0.060
3	94655	0.058

Price($)	Vol.	No.
0.064	215185	2
0.065	624150	4
0.067	135766	2
0.068	1050000	2
0.069	100000	1

Last trade - 16.10pm 30/07/2025 (20 minute delay)

SNT (ASX) Chart

Just stumbled upon this analyst, calls Geron a buy and 12 month...

Haranga jumps +7% on Lincoln acquisition

ASX Market Close: Index rebounds as investors buoyant | July 30, 2025

HotCopper Trends: Wall of quarterlies dominate; then there's Micro-X & Ionic

Neurizon inks $1.5M loan against R&D Tax Rebate

Ionic Rare Earths falls -7% as momentum slips on vague production update

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Just stumbled upon this analyst, calls Geron a buy and 12 month...

Top Stories

Haranga jumps +7% on Lincoln acquisition

ASX Market Close: Index rebounds as investors buoyant | July 30, 2025

HotCopper Trends: Wall of quarterlies dominate; then there's Micro-X & Ionic

Neurizon inks $1.5M loan against R&D Tax Rebate

Ionic Rare Earths falls -7% as momentum slips on vague production update

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News